山东省VATS/RATS非小细胞肺癌围术期质量控制专家共识(2026版)

doi:10.6040/j.issn.1671-7554.0.2026.0971

摘要/Abstract

摘要： 肺癌在全球和中国范围内的发病率和死亡率均位居癌症全系首位,早期肺癌最基本、最有效的治疗方式是手术切除。在“健康中国2030”规划背景下,相关政策、指南出台指导癌症诊疗质量控制,肺癌是诊疗质控的主要癌种之一。基于此,山东省腔镜外科质控中心胸腔镜委员会于2025年制定了山东省电视辅助胸腔镜手术(video-assisted thoracoscopic surgery, VATS)/ 机器人辅助胸腔镜手术(robot-assisted thoracoscopic surgery, RATS)非小细胞肺癌围术期质量控制专家共识。在2025版《共识》运行过程中,山东省各地医疗机构积累了宝贵的临床经验,也反馈了若干可进一步优化和细化的质控细节,山东省医学会胸外科分会总结2025年质控经验,更新形成了《山东省VATS/RATS非小细胞肺癌围术期质量控制专家共识(2026版)》,推动山东省胸外科非小细胞肺癌围术期管理水平向更加精准、高效的方向持续迈进。

关键词: 非小细胞肺癌, 胸腔镜手术, 围术期, 质量控制, 专家共识

Abstract: Lung cancer ranks first in both incidence and mortality among all malignancies worldwide and in China. Surgical resection remains the most effective treatment for early-stage non-small cell lung cancer(NSCLC). In alignment with the "Healthy China 2030" initiative, a series of policies and guidelines have been introduced to enhance quality control in cancer diagnosis and treatment, with lung cancer identified as one of the priority cancer types for such oversight. In response, the Thoracoscopy Committee of the Shandong Provincial Endoscopic Surgery Quality Control Center developed the Shandong Provincial Expert Consensus on Perioperative Quality Control for Video-Assisted Thoracoscopic Surgery(VATS)/Robot-Assisted Thoracoscopic Surgery(RATS)in Non-Small Cell Lung Cancer(2025 Edition). During its implementation, medical institutions across Shandong Province accumulated substantial clinical experience and provided constructive feedback regarding several quality control aspects that could be further optimized. Based on this feedback and a comprehensive review of the 2025 experience, the Thoracic Surgery Branch of the Shandong Medical Association has updated and refined the consensus, resulting in the present 2026 Edition. This updated version is intended to promote continuous improvement and guide perioperative management of NSCLC toward greater precision and efficiency across thoracic surgery practice in Shandong Province.

Key words: Non-small cell lung cancer, Thoracoscopic surgery, Perioperative period, Quality control, Expert consensus

中图分类号:

R734.2

山东省医学会胸外科分会(). 山东省VATS/RATS非小细胞肺癌围术期质量控制专家共识(2026版)[J]. 山东大学学报 (医学版), 2026, 64(9): 1-7.

Thoracic Surgery Branch, Shandong Medical Association. Shandong Provincial expert consensus on perioperative quality control for VATS/RATS in non-small cell lung cancer(2026 Edition)[J]. Journal of Shandong University (Health Sciences), 2026, 64(9): 1-7.

参考文献

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians, 2024, 74(3): 229-263.
[2] Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
[3] Lin Z, Cheng X. The future and challenges of robotics in lung cancer surgery[J]. Tumor, 2024, 44(6): 631-641.
[4] Casiraghi M, Cara A, Mazzella A et al. 1000 Robotic-assisted lobectomies for primary lung cancer: 16 years single center experience[J]. Lung Cancer,2024, 195:107903. DOI: 10.1016/j.lungcan.2024.107903
[5] 山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报(医学版), 2025, 63(12): 1-5.
[6] Forde P M, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer[J]. N Engl J Med, 2022, 386(21): 1973-1985.
[7] Cascone T, Awad M M, Spicer J D, et al. Perioperative Nivolumab in resectable lung cancer[J]. N Engl J Med, 2024, 390(19): 1756-1769.
[8] Heymach J V, Harpole D, Mitsudomi T, et al. Perioperative Durvalumab for resectable non-small-cell lung cancer[J]. N Engl J Med, 2023, 389(18): 1672-1684.
[9] Spicer J D, Garassino M C, Wakelee H, et al. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer(KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet, 2024, 404(10459): 1240-1252.
[10] Feldman H, Sepesi B, Leung C H, et al. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer [J]. J Thorac Cardiovasc Surg, 2024, 167(4): 1444-1453.
[11] NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version5.2026 [EB/OL]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450.
[12] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南 2026[M]. 北京: 人民卫生出版社, 2026: 4.
[13] 中华医学会肿瘤学分会. 中华医学会肺癌临床诊疗指南(2024版)[J]. 中华医学杂志, 2024, 104(34): 3175-3213.
[14] Wakelee H A, Altorki N K, Zhou C, et al. IMpower010: Final disease-free survival(DFS)and second overall survival(OS)interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer(NSCLC)[C]. ASCO Annual Meeting, 2024.
[15] Wu Y L, Dziadziuszko R, Ahn J S, et al. Alectinib in resected ALK-positive non-small-cell lung cancer[J]. N Engl J Med, 2024, 390(14): 1265-1276.
[16] Wu Y L, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(18): 1711-1723.
[17] Herbst R S, Wu Y L, John T, et al. Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial[J]. J Clin Oncol, 2023, 41(10): 1830-1840.
[18] Hung H Y, Tseng Y H, Chao H S, et al. Multidisciplinary team discussion results in survival benefit for patients with stage III non-small-cell lung cancer[J]. PLoS One, 2020, 15(10): e0236503. DOI:10.1371/journal.pone.0236503
[19] Yamamichi T, Ichinose J, Omura K et al. Impact of postoperative complications on the long-term outcome in lung cancer surgery[J]. Surg Today, 2022, 52(9): 1254-1261.

相关文章 15

[1]	梁晨,姚丽娟,吕龙飞,唐泽,秦达,崔有斌,余孝淇. 三维重建联合CT引导下穿刺定位在微创治疗肺磨玻璃结节中的应用[J]. 山东大学学报 (医学版), 2026, 64(5): 74-82.
[2]	黄佩文, 王旭东. 治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin[J]. 山东大学学报 (医学版), 2026, 64(3): 124-130.
[3]	中国医师协会骨科医师分会智能骨科学组,中华预防医学会脊柱疾病预防与控制专业委员会脊柱脊髓损伤疾病预防与控制学组. 人工智能脊柱退变影像学测量位点与标注专家共识(2025)[J]. 山东大学学报 (医学版), 2026, 64(2): 1-10.
[4]	机器人辅助经椎间孔腰椎椎体间融合术手术技术专家组. 机器人辅助经椎间孔腰椎椎体间融合术专家共识[J]. 山东大学学报 (医学版), 2026, 64(2): 11-21.
[5]	赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85.
[6]	徐年兴,魏东,乔俊杰,战炳炎. CD8⁺、IL-6和PaO₂对不可切除Ⅲ_B/C和Ⅳ期非小细胞肺癌免疫治疗触发放射召回性肺炎的预测价值[J]. 山东大学学报 (医学版), 2025, 63(2): 29-35.
[7]	山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报 (医学版), 2025, 63(12): 1-5.
[8]	刘振昆,吕纪玲,徐伟伟,马力天,张才擎. BALF tNGS检测及培养对NSCLC合并IPFD的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(11): 36-45.
[9]	山东省医学会乳腺疾病多学科联合委员会. 乳腺癌多学科协作诊疗山东共识(2024年版)[J]. 山东大学学报 (医学版), 2025, 63(1): 10-16.
[10]	张荣雨,赵文,李洪欣,杨闯,王健,韩春燕,李际盛. 奥西替尼联合化疗一线治疗EGFR-RAD51融合突变转移性肺腺癌1例[J]. 山东大学学报 (医学版), 2024, 62(5): 116-120.
[11]	张杨,李晓旭. 加速康复外科理念在骨折治疗中的研究进展[J]. 山东大学学报 (医学版), 2024, 62(10): 18-25.
[12]	华裔骨科学会骨科康复专业委员会. 全膝关节置换术后膝关节功能加速康复专家共识[J]. 山东大学学报 (医学版), 2024, 62(10): 48-61.
[13]	执笔专家: 班艳丽, 赵颖, 李桦, 刘薇, 荣风年, 赵淑萍, 崔保霞. 剖宫产子宫瘢痕妊娠实用临床分型诊治专家共识[J]. 山东大学学报 (医学版), 2023, 61(11): 1-10.
[14]	秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[15]	陈兆波,方敏,薛浩然,刘春艳. 去泛素化酶USP35促进非小细胞肺癌细胞迁移和侵袭[J]. 山东大学学报 (医学版), 2022, 60(4): 30-37.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed